{
    "nct_id": "NCT04463771",
    "official_title": "An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)",
    "inclusion_criteria": "* Ability to comprehend and willingness to sign a written ICF for the study. Note for Germany: This excludes individuals who are housed in an institution due to official or court order Women 18 years of age or older (or as applicable per local country requirements).\n* Histologically confirmed diagnosis of advanced or metastatic endometrial cancer with disease progression on or after treatment with at least 1 platinum-containing regimen for advanced or metastatic disease.\n* Groups A, B, and E: Have not been previously treated with a PD-(L)1 inhibitor.\n* Group A only: Tumor tissue tested as MSI-High\n* Group B only: Tumor tissue tested as deficient MMR or an ultra-mutated POLE tumor.\n* Group D only: Tumor tissue tested as having an FGFR 1,2,3 mutation or alteration characterized as per protocol.\n* Group E: Tumor tissue tested as MSS and PD-L1 positive.\n* Group F: Radiological evidence of disease progression on or after prior PD (L)1 therapy and Tumor tissue tested as MSI-H\n* Must have at least 1 measurable tumor lesion per RECIST v1.1.\n* Willing to provide tumor tissue sample (fresh or archived).\n* ECOG performance status 0 to 1.\n* Willingness to avoid pregnancy.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Group A, B and E only: Histologically confirmed diagnosis of carcinosarcoma of the uterus.\n* Histologically confirmed diagnosis of sarcoma of the uterus.\n* Has disease eligible for potentially curative treatment.\n* Receipt of anticancer therapy within 28 days of the first administration of study treatment, with the exception of localized radiotherapy.\n* Toxicity of prior therapy that has not recovered to â‰¤ Grade 1 or baseline unless approved by the medical monitor.\n* Groups C, D and F (combinations): limiting immune-related toxicity during prior checkpoint inhibitor therapy.\n* Group F only: Previous treatment with LAG-# or TIM-3 therapy or lenvatinib; multiple metastases that achieved mixed tumor response to prior anti-PD-(L)1 therapy\n* Has an active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 14 days before the first dose of study treatment.\n* Receiving chronic systemic steroids (> 10 mg/day of prednisone or equivalent):\n* Known active CNS metastases and/or carcinomatous meningitis.\n* Has known active hepatitis B or C.\n* Has received a live vaccine within 28 days of the planned start of study treatment.\n* Evidence of interstitial lung disease or active, noninfectious pneumonitis.\n* Participants who are known to be HIV-positive with some protocol exceptions.",
    "miscellaneous_criteria": ""
}